Search Results for “mental health” – Page 48 – media

Nicotine in E-cigarettes damages DNA, mouse study suggests

The nicotine in e-cigarettes seems to damage DNA in ways that may increase cancer risk, a new study in mice suggests.
- Source: medicalxpress
- 610
- February 6, 2018
cancer DNA e-cigarettes nicotine Researches
Augmented Reality Helps Surgeons ‘See Through’ Tissue & Reconnect Blood Vessels

Surgeons use Microsoft HoloLens headsets while operating on patients undergoing reconstructive lower limb surgery.
- Source: ODT
- 582
- February 2, 2018
augmented reality medical device Researches surgery
FDA Clears UC Davis Startup’s Polymer to Aid Bone Regrowth

Molecular Matrix Inc. invented a synthetic bone void filler, Osteo-P, that can help injured bones regrow.
- Source: ODT
- 605
- February 1, 2018
bone FDA medical device
Ddu College — China’s Import and Export Report of Peptic Ulcer Drugs

Peptic ulcers are open sores that develop on the inside lining of your stomach and the upper portion of your small intestine. The most common symptom of a peptic ulcer is stomach pain.
- Source: Ddu
- 42,735
- January 25, 2018
Ddu College Peptic ulcers
Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer

Celgene agreed on Monday to buy the rest of Juno Therapeutics it doesn't already own for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.
- Source: Cnbc
- 982
- January 24, 2018
cancer CAR–T Market Views
Diagnostic Products of the Future

Panelists at the recent J.P. Morgan Healthcare Conference in San Francisco, CA were charged with separating the hype from the reality in the field of diagnostics and offered insight into what products will win in the space.
- Source: MDDI Online
- 777
- January 23, 2018
diagnostics healthcare technologies and innovations medical device Researches
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL

Novartis today announced that its supplemental Biologics License Application (sBLA) for KymriahTM (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are ineligible for or relapse after autologous stem cell transplant (ASCT) has been accepted by the US Food and Drug Administration (FDA) for Priority Review.
- Source: Novartis
- 403
- January 18, 2018
DLBCL New Approvals sBLA
Afatinib Approval Expanded for Rare Lung Cancer Treatment

Boehringer Ingelheim announced the approval of a new indication for afatinib (Gilotrif), as the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (NDA) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
- Source: Raredr
- 710
- January 17, 2018
afatinib DNA FDA New Approvals NSCLC
UK Takes Stricter Stance on Human Factors Engineering for Medical Devices

Recent guidance from UK medical device market regulators on human factors engineering (HFE) includes some recommendations that differ from HFE requirements established in Europe, suggesting a more standalone British approach to some areas of device development.
- Source: Emergo
- 588
- January 15, 2018
FDA medical device Policy
Alzheimer’s Drug Turns Back Clock in Powerhouse of Cell

The experimental drug J147 is something of a modern elixir of life; it’s been shown to treat Alzheimer’s disease and reverse aging in mice and is almost ready for clinical trials in humans.
- Source: Neuroscience News
- 593
- January 12, 2018
Alzheimer's disease Clinical Trials Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.